These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32785819)

  • 1. Treatment outcomes of IgG4-producing marginal zone B-cell lymphoma: a retrospective case series.
    Sumii Y; Asada N; Sato Y; Ohshima KI; Makita M; Yoshimoto Y; Sogabe Y; Imajo K; Meguri Y; Ennishi D; Nishimori H; Fujii N; Matsuoka KI; Yoshino T; Maeda Y
    Int J Hematol; 2020 Dec; 112(6):780-786. PubMed ID: 32785819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and outcomes of IgG4-positive marginal zone lymphoma: Systematic scoping review.
    Nishimura Y; Wien EA; Nishimura MF; Nishikori A; Sato Y; Otsuka F
    Pathol Int; 2022 Jul; 72(7):361-370. PubMed ID: 35678201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical characteristics and treatment results of ocular adnexal lymphoma.
    Woo JM; Tang CK; Rho MS; Lee JH; Kwon HC; Ahn HB
    Korean J Ophthalmol; 2006 Mar; 20(1):7-12. PubMed ID: 16768184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome.
    Tsang RW; Gospodarowicz MK; Pintilie M; Wells W; Hodgson DC; Sun A; Crump M; Patterson BJ
    J Clin Oncol; 2003 Nov; 21(22):4157-64. PubMed ID: 14615444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of Upfront Therapy for Marginal Zone Lymphoma.
    Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A subset of ocular adnexal marginal zone lymphomas may arise in association with IgG4-related disease.
    Ohno K; Sato Y; Ohshima K; Takata K; Miyata-Takata T; Takeuchi M; Gion Y; Tachibana T; Orita Y; Ito T; Swerdlow SH; Yoshino T
    Sci Rep; 2015 Aug; 5():13539. PubMed ID: 26311608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Kang HJ; Choi CW; Park J; Kim HJ; Kwon JH; Lee HS; Lee GW; Eom HS; Kwak JY; Lee WS; Suh C; Kim HJ
    Int J Hematol; 2010 Oct; 92(3):510-7. PubMed ID: 20838958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marginal zone lymphomas involving meningeal dura: possible link to IgG4-related diseases.
    Venkataraman G; Rizzo KA; Chavez JJ; Streubel B; Raffeld M; Jaffe ES; Pittaluga S
    Mod Pathol; 2011 Mar; 24(3):355-66. PubMed ID: 21102421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
    Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
    Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage I and II MALT lymphoma: results of treatment with radiotherapy.
    Tsang RW; Gospodarowicz MK; Pintilie M; Bezjak A; Wells W; Hodgson DC; Crump M
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1258-64. PubMed ID: 11483337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cutaneous marginal zone lymphomas with plasmacytic differentiation show frequent IgG4 expression.
    Brenner I; Roth S; Puppe B; Wobser M; Rosenwald A; Geissinger E
    Mod Pathol; 2013 Dec; 26(12):1568-76. PubMed ID: 23765244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
    Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
    Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
    Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype.
    Portell CA; Aronow ME; Rybicki LA; Macklis R; Singh AD; Sweetenham JW
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):203-10. PubMed ID: 24417911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
    Brown JR; Friedberg JW; Feng Y; Scofield S; Phillips K; Dal Cin P; Joyce R; Takvorian RW; Fisher DC; Fisher RI; Liesveld J; Marquis D; Neuberg D; Freedman AS
    Br J Haematol; 2009 Jun; 145(6):741-8. PubMed ID: 19344412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.
    Conconi A; Raderer M; Franceschetti S; Devizzi L; Ferreri AJ; Magagnoli M; Arcaini L; Zinzani PL; Martinelli G; Vitolo U; Kiesewetter B; Porro E; Stathis A; Gaidano G; Cavalli F; Zucca E
    Br J Haematol; 2014 Jul; 166(1):69-76. PubMed ID: 24673512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients.
    Uno T; Isobe K; Shikama N; Nishikawa A; Oguchi M; Ueno N; Itami J; Ohnishi H; Mikata A; Ito H
    Cancer; 2003 Aug; 98(4):865-71. PubMed ID: 12910532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
    Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
    Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary spinal marginal zone lymphoma: case report and review of the literature.
    Ahmadi SA; Frank S; Hänggi D; Eicker SO
    Neurosurgery; 2012 Aug; 71(2):E495-508; discussion E508. PubMed ID: 22314752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide plus rituximab (R
    Becnel MR; Nastoupil LJ; Samaniego F; Davis RE; You MJ; Green M; Hagemeister FB; Fanale MA; Fayad LE; Westin JR; Wang M; Oki Y; Forbes SG; Feng L; Neelapu SS; Fowler NH
    Br J Haematol; 2019 Jun; 185(5):874-882. PubMed ID: 30919940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.